GlobalData on MSN8d
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...
MedPage Today5d
Which Analgesic is Best for Acute Pediatric Pain?
Opens in a new tab or window NSAIDs, ketamine, and mid- to high-potency opioids reduced acute pediatric pain, but effects were modest NSAIDs provided the greatest benefit and the least harm ...
Managed Healthcare Executive7d
FDA Approves Journavx, New Nonopioid Med, for Acute Pain
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Healio8d
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
WNYT NewsChannel 138d
FDA approves new nonopioid painkiller for acute pain
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid painkiller that could change the way doctors treat acute pain.
Yahoo Finance8d
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective ...